LDLin Ding

Lin Ding

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lin Ding has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Jing Shang

    State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China

    3 shared publications
  • Waseem Hassan

    National Center for Drug Screening and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Jiangsu Province 210009, PR China

    2 shared publications
  • Daoud Abdelkader

    National Center for Drug Screening and State Key Laboratory of Natural Medicines

    1 shared publication
  • Fangrong Yan

    Department of Biostatistics, China Pharmaceutical University, Nanjing, China

    1 shared publication
  • Jun Liu

    National Center for Drug Screening and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Jiangsu Province 210009, PR China

    1 shared publication
  • Junlin Liu

    Department of Dermatology The Second Affiliated Hospital of Hainan Medical University Haikou China

    1 shared publication

Latest Publications

  • Open Access

    Lipid modulatory activities of Cichorium glandulosum Boiss et Huet are mediated by multiple components within hepatocytes

    by Lin Ding, Jun-Lin Liu, Waseem Hassan, Lu-Lu Wang, Fang-Rong Yan, Jing Shang

    To investigate a possible methodology of exploiting herbal medicine and design polytherapy for the treatment of non-alcoholic fatty liver disease (NAFLD), we have made use of Cichorium glandulosum Boiss et Huet (CG), a traditional Chinese herbal medicine that has been proven to be effective in treating hepatic diseases. Here, we report that the extract of CG effectively reduced lipid accumulation under conditions of lipid overloading in vivo and in vitro (in a rat high-fat diet model and a hepG2 cell model of free fatty acid treatment). CG extract also protected hepatocytes from injury and inflammation to aid its lipid-lowering properties (in a rat high-fat diet model and a L02 cell model of acetaminophen treatment). Serum chemistry analysis accompanied by in vitro drug screening confirmed that CG-4, CG-10 and CG-14 are the lipo-effective components of CG. Western blotting analysis revealed that these components can regulate key lipid targets at the molecular level, including CD36, FATP5 and PPAR-[agr], thus the lipid oxidation and lipid absorption pathways. Finally, we adopted the experimental design and statistical method to calculate the best combination proportion (CG-4: CG-10: CG-14 = 2.065: 1.782: 2.153) to optimize its therapeutic effect.


  • Interleukin-6 signal transduction and its role in hepatic lipid metabolic disorders

    by Waseem Hassan, Lin Ding, Rong-Yin Gao, Jun Liu, Jing Shang


  • Open Access

    Adipokines and Hepatic Insulin Resistance

    by Yu Li, Lin Ding, Waseem Hassan, Daoud Abdelkader, Jing Shang

    Obesity is a major risk factor for insulin resistance and type 2 diabetes. Adipose tissue is now considered to be an active endocrine organ that secretes various adipokines such as adiponectin, leptin, resistin, tumour necrosis factor-α, and interleukin-6. Recent studies have shown that these factors might provide a molecular link between increased adiposity and impaired insulin sensitivity. Since hepatic insulin resistance plays the key role in the whole body insulin resistance, clarification of the regulatory processes about hepatic insulin resistance by adipokines in rodents and human would seem essential in order to understand the mechanism of type 2 diabetes and for developing novel therapeutic strategies to treat it.